1
|
Salah S, Sughayer MA, Jaber O, Abu Abed N, Ajlouni F, Al Gargaz W, Abu Hijlih R, Abuhijla F, Al-Ibraheem A, Alul F, Naser W. A Rare Case of Nasal Sarcoma with BCOR Internal Tandem Duplication Showing Complete Pathologic Response to the VDC-IE Chemotherapy Protocol. Case Rep Oncol Med 2023; 2023:5546323. [PMID: 38170001 PMCID: PMC10761225 DOI: 10.1155/2023/5546323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2023] [Revised: 12/12/2023] [Accepted: 12/15/2023] [Indexed: 01/05/2024] Open
Abstract
Sarcoma with BCOR genetic alteration is an exceptionally rare and emerging subtype of sarcoma. It is categorized into two types: BCOR-related gene fusions such as BCOR::CCNB3 sarcomas and other BCOR-rearranged sarcoma and sarcomas with internal tandem duplication of BCOR genes such as infantile undifferentiated round cell sarcomas and primitive myxoid mesenchymal tumors of infancy. BCOR::CCNB3 sarcomas predominantly arise in bone rather than soft tissue and exhibit a higher occurrence in children and adolescent males, whereas sarcomas with BCOR internal tandem duplication show a wider age range but usually arise in the first year of life. Due to their rarity, there is ongoing debate and uncertainty regarding the best treatment approach, with a lack of specific clinical trials addressing these tumors. In this report, we present a unique case of sarcoma with internal tandem duplication of BCOR gene originating in the nasal region. The tumor was successfully and completely resected using the standard VDC-IE chemotherapy protocol, resulting in an unprecedented 100 percent tumor necrosis. The patient has completed the protocol and remains recurrence-free 13 months after diagnosis. This case suggests potential efficacy of the standard VDC-IE protocol in achieving remarkable responses in BCOR rearrangement sarcomas, including the internal tandem duplication subtype. However, further studies are needed to determine the optimal treatment strategies for this disease.
Collapse
Affiliation(s)
- Samer Salah
- Department of Medical Oncology, King Hussein Cancer Center, Amman, Jordan
| | | | - Omar Jaber
- Department of Pathology, King Hussein Cancer Center, Amman, Jordan
| | - Nebras Abu Abed
- Department of Medical Oncology, King Hussein Cancer Center, Amman, Jordan
| | - Fatena Ajlouni
- Department of Radiology, King Hussein Cancer Center, Amman, Jordan
| | - Wisam Al Gargaz
- Department of Surgery, King Hussein Cancer Center, Amman, Jordan
- Department of Special Surgery, Jordan University of Science and Technology, Irbid, Jordan
| | - Ramiz Abu Hijlih
- Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan
| | - Fawzi Abuhijla
- Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan
| | - Akram Al-Ibraheem
- Department of Nuclear Medicine, King Hussein Cancer Center, Amman, Jordan
| | - Farah Alul
- Department of Cell Therapy and Applied Genomics, King Hussein Cancer Center, Amman, Jordan
| | - Walid Naser
- Department of Cell Therapy and Applied Genomics, King Hussein Cancer Center, Amman, Jordan
| |
Collapse
|